IRIS
BOGLIONE, Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.309
NA - Nord America 3.145
AS - Asia 2.497
SA - Sud America 686
Continente sconosciuto - Info sul continente non disponibili 167
AF - Africa 96
Totale 9.900
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.027
RU - Federazione Russa 1.061
IE - Irlanda 945
SG - Singapore 785
CN - Cina 530
BR - Brasile 519
VN - Vietnam 435
HK - Hong Kong 418
SE - Svezia 310
IT - Italia 275
UA - Ucraina 222
FR - Francia 158
DE - Germania 157
AR - Argentina 75
ID - Indonesia 63
CA - Canada 62
BD - Bangladesh 60
GB - Regno Unito 40
IN - India 40
KR - Corea 32
MX - Messico 32
ZA - Sudafrica 27
EC - Ecuador 25
FI - Finlandia 23
VE - Venezuela 22
BE - Belgio 20
IQ - Iraq 20
BJ - Benin 19
JP - Giappone 19
CO - Colombia 18
PY - Paraguay 17
EU - Europa 15
NL - Olanda 15
AT - Austria 13
MA - Marocco 12
ES - Italia 11
PL - Polonia 10
TR - Turchia 10
SA - Arabia Saudita 9
CZ - Repubblica Ceca 8
NP - Nepal 8
RO - Romania 8
DZ - Algeria 7
KE - Kenya 7
UZ - Uzbekistan 7
CL - Cile 6
EG - Egitto 6
IL - Israele 6
IR - Iran 6
JM - Giamaica 6
PH - Filippine 6
TN - Tunisia 6
BG - Bulgaria 5
LT - Lituania 5
PK - Pakistan 5
TH - Thailandia 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
ET - Etiopia 4
HU - Ungheria 4
JO - Giordania 4
KZ - Kazakistan 4
RS - Serbia 4
BB - Barbados 3
CH - Svizzera 3
KG - Kirghizistan 3
LB - Libano 3
QA - Qatar 3
TT - Trinidad e Tobago 3
AL - Albania 2
CR - Costa Rica 2
DK - Danimarca 2
GT - Guatemala 2
HN - Honduras 2
MD - Moldavia 2
MY - Malesia 2
NO - Norvegia 2
PA - Panama 2
PE - Perù 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BW - Botswana 1
BZ - Belize 1
CY - Cipro 1
DM - Dominica 1
GA - Gabon 1
GE - Georgia 1
GM - Gambi 1
LV - Lettonia 1
MK - Macedonia 1
ML - Mali 1
PS - Palestinian Territory 1
PT - Portogallo 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TG - Togo 1
Totale 9.747
Salva come PNG Salva come JPEG
Città #
Dublin 929
Hong Kong 415
Jacksonville 375
Singapore 314
Council Bluffs 299
San Jose 259
Ashburn 181
Beijing 169
Ho Chi Minh City 143
Moscow 130
Lauterbourg 122
Wilmington 121
Princeton 120
Lawrence 118
Columbus 116
Chandler 108
San Mateo 106
Los Angeles 90
Hanoi 89
Munich 56
Santa Clara 55
São Paulo 55
Buffalo 44
New York 31
Redondo Beach 31
Seoul 31
Dallas 30
Dong Ket 30
Jakarta 30
Piemonte 26
Ann Arbor 25
Orem 25
Boardman 23
Brussels 19
Cotonou 19
Tianjin 19
Houston 18
Montreal 17
Novara 17
Frankfurt am Main 16
Milan 16
Nuremberg 16
Tokyo 16
Da Nang 15
Shanghai 15
Turin 15
Haiphong 14
Norwalk 14
Rio de Janeiro 14
Guangzhou 13
Helsinki 13
Johannesburg 13
Mexico City 13
Toronto 13
Dhaka 12
Denver 11
Falkenstein 11
London 11
Amsterdam 10
Brooklyn 10
Guayaquil 10
Porto Alegre 10
Rome 10
San Francisco 10
Thái Bình 10
Belo Horizonte 9
Chennai 9
Hangzhou 9
Quito 9
Turku 9
Andover 8
Biên Hòa 8
Fairfield 8
Hải Dương 8
Naples 8
Philadelphia 8
Warsaw 8
Atlanta 7
Brasília 7
Brno 7
Caracas 7
Casablanca 7
Manchester 7
San Diego 7
Sylmar 7
Tashkent 7
Alessandria 6
Baghdad 6
Cape Town 6
Chicago 6
Curitiba 6
Horia 6
Nairobi 6
Phoenix 6
Vienna 6
West Jordan 6
Woodbridge 6
Asunción 5
Boston 5
Buenos Aires 5
Totale 5.381
Salva come PNG Salva come JPEG
Nome #
Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients 263
Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19 204
Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19 193
A UHPLC-MS/MS method for the quantification of currently used direct antiviral agents in human plasma and evaluation of "normalized matrix effect" 111
A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma 110
Antiviral therapy in patients with HBV treated for tuberculosis: a forgotten issue 107
A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir 107
VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia 105
Coinfection with other respiratory pathogens in COVID-19 patients 103
Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients 101
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients 99
A Possible Role of Therapeutic Drug Monitoring in Virological Breakthrough during Simeprevir and PEG-IFN Treatment in HCV-4 98
Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients 98
A Case of Imported JE Acquired During Short Travel in Vietnam. Are Current Recommendations About Vaccination Broader? 97
Evaluation of intracellular and plasma pharmacokinetics, pharmacogenetics and clinical features in HBV e antigen-negative patients treated with entecavir 97
Clinical Characteristics and Outcomes in Patients with Chronic HBV Infection and Hospitalized for COVID-19 Pneumonia: A Retrospective Cohort Study 96
Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy 95
ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy 94
Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis 94
Ceftobiprole perspective: Current and potential future indications 94
Prevalenza e fattori di rischio dell'insorgenza di psicosi acuta 59 nei pazienti anziani ospedalizzati per infezione da Sars-COV-2: studio retrospettivo 94
A concentration-dependent pharmacokinetic interaction with telaprevir increases ribavirin concentrations and leads to higher haemoglobin drop 93
Development and validation of a useful UPLC-MS/MS method for quantification of total and phosphorylated-ribavirin in peripheral blood mononuclear cells of HCV+ patients 91
[Primary soft tissue and tenosynovial tuberculosis after needlestick injury in a surgeon] 90
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 90
A rare SARS-CoV-2 complication: Candida spondylodiscitis following SARS-CoV-2 infection—two case reports 89
Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all? 88
Lo studio filologico applicato alla descrizione della “pestilenza” di Atene di Tucidide: dall’analisi del testo agli aspetti di epidemiologia e malattie infettive 88
Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage 87
Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients 86
Retreatment with sofosbuvir/velpatasvir in cirrhotic patients with genotype-4 who failed a previous interferon-free regimen: A case series 86
F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy 86
Virological response and safety in a cohort of immigrant patients affected by chronic hepatitis delta treated with PEG-IFN 84
Are detectable sofosbuvir trough concentrations predictive of virological failure during anti-HCV treatment? Preliminary evidences from the KINETI-C study 83
Prospective evaluation of qHBsAg decline in patients affected by chronic hepatitis B, E genotype, treated with entecavir or tenofovir 83
Long-COVID syndrome in hospitalized patients after 2 years of follow-up 82
Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B 82
EPATITE CRONICA DA HBV DI GENOTIPO E NELLA POPOLAZIONE IMMIGRATA PROVENIENTE DALL'AFRICA OCCIDENTALE 81
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 81
The proper use of corticosteroids for 2019-nCov pneumonia: Towards promising results? 81
Daclatasvir Plasma Levels in a Cohort of Patients with Hepatitis C Virus Infection Taking Methadone: A Prospective Analysis 80
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells 80
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy 80
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy 80
HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing 78
Combination therapy in chronic hepatitis B: what are the real benefits? 77
Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir 77
Development and validation of an UPLC MS-MS method for the quantification of new direct antiretroviral agents simeprevir, daclatasvir sofosbuvir and its metabolite GS-332007 in human plasma 77
Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? 77
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens 76
Visceral leishmaniasis in a patient with active HBV/HDV co-infection 75
Behavioural health issues in post coronavirus disease (COVID) syndrome and suicide risk: a narrative review 74
Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry 74
Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study 74
Clinical characteristics and outcomes in hospitalized patients with West Nile neuroinvasive disease: A case-series analysis 73
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 72
Role of simeprevir plasma concentrations in HCV treated patients with dermatological symptoms 72
Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population 72
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 72
Liver involvement and mortality in COVID-19: A retrospective analysis from the CORACLE study group 72
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients 71
Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis 71
Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E 71
Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study 71
The co-administration of telaprevir increases ribavirin plasma and intra-erythrocytic concentrations, causing higher onset of anemia 70
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes 70
Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors 70
UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients 70
Epidemiology, patient profile, and health care resource use for hepatitis C in Italy 70
Reasons to wait or to treat naive patients affected by chronic hepatitis C with low fibrosis stage and genotypes 2 or 3 70
Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C 70
Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon 70
Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon 69
Real-World Outcomes of Neutralizing Monoclonal Antibody Treatment in Patients Affected by Nosocomial Coronavirus Disease 2019 68
Triple or dual therapy for HCV-1 naive patients? Optimizing selection tools 68
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 68
Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B 68
Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy 67
Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry 66
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 66
Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment 66
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms 66
Predictors of Mortality in Patients with COVID-19 Infection in Different Health- Care Settings: A Retrospective Analysis from a CORACLE Study Group 65
Plasmatic and intracellular concentration of entecavir during treatment of a symptomatic flare in HBV-HDV decompensated cirrhosis 65
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics 65
Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir 65
Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders 65
Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon 65
Response to: Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis 65
Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: a case-control study 65
Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes 64
Pharmacogenetics of the anti-HCV drug sofosbuvir: a preliminary study 64
Pharmacogenetic analysis of hepatitis C virus related mixed cryoglobulinemia 64
Early ribavirin concentration is a critical response factor in the sub-population of patients infected by HCV-1 and unfavourable IL28B genotype 64
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 63
Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study 63
Influence of ABCB11 and HNF4α genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study 63
Letter: liver involvement and mortality in COVID-19—the role of anti-viral therapy should be considered 63
Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy 63
Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-naïve patients with chronic hepatitis B 62
Totale 8.272
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.341
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.341
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022665 0 10 126 47 20 21 27 16 93 24 120 161
2022/20231.564 135 111 89 24 36 89 33 61 913 13 44 16
2023/2024441 26 19 18 9 64 6 116 15 13 10 7 138
2024/20251.438 14 11 100 25 14 67 186 157 432 201 40 191
2025/20264.513 176 206 445 828 278 304 617 670 278 314 168 229
2026/2027506 242 264 0 0 0 0 0 0 0 0 0 0
Totale 9.900